Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
High Conviction Trades
Discover high conviction trades that caused a significant change in a fund's stake in a stock
Fund Manager Portfolios
Gain insights from the world’s largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
CVRx
CVRX
Market cap
$245M
Overview
Fund Trends
Analyst Outlook
Journalist POV
9.36
USD
-0.04
0.43%
At close
Updated
Dec 2, 9:37 AM EST
Pre-market
After hours
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
-0.43%
5 days
-5.26%
1 month
-9.65%
3 months
21.09%
6 months
44.44%
Year to date
-31.08%
1 year
-39.69%
5 years
-66.57%
10 years
-66.57%
Upgrade to unlock
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
100%
Negative
Positive
Neutral
Negative
Neutral
GlobeNewsWire
13 days ago
CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference
MINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025. The fireside chat is scheduled at 2:00 p.m. (ET) the same day via webcast.
Neutral
Seeking Alpha
26 days ago
CVRx, Inc. (CVRX) Q3 2025 Earnings Call Transcript
CVRx, Inc. ( CVRX ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Kevin Hykes - President, CEO & Director Jared Oasheim - Chief Financial Officer Conference Call Participants Mike Vallie - Westwicke Partners, LLC John Young - Canaccord Genuity Corp., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Rohin Patel - JPMorgan Chase & Co, Research Division Max Smock Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Presentation Operator Greetings, and welcome to the CVRx Third Quarter 2025 Earnings Conference Call. As a reminder, this conference is being recorded.
Neutral
Zacks Investment Research
26 days ago
CVRx (CVRX) Reports Q3 Loss, Beats Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.57 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025
MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1- 877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.
Positive
The Motley Fool
3 months ago
CVRx (CVRX) Q2 Revenue Jumps 15%
CVRx (CVRX) Q2 Revenue Jumps 15%
Neutral
Seeking Alpha
3 months ago
CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:09 PM ET CVRx, Inc. (NASDAQ:CVRX ) Q2 2025 Earnings Conference Call August 04, 2025, 04:30 PM ET Company Participants Jared Oasheim - Chief Financial Officer Kevin Hykes - President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division John Edward Young - Canaccord Genuity Corp., Research Division Rohin Kirit Patel - JPMorgan Chase & Co, Research Division Ross Everett Osborn - Cantor Fitzgerald & Co., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Michael Vallie - Unidentified Company Operator Good afternoon, ladies and gentlemen.
Neutral
Zacks Investment Research
3 months ago
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.65 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
CVRx Reports Second Quarter 2025 Financial and Operating Results
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025.
Neutral
GlobeNewsWire
4 months ago
CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast.
Negative
Zacks Investment Research
4 months ago
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
High Conviction Trades
Discover high conviction trades that caused a significant change in a fund's stake in a stock
Fund Manager Portfolios
Gain insights from the world’s largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close